AI Tool Uses MRI to Predict Alzheimer's Treatment Response Without PET Scans
NeuroXT and BIDMC expand their AI-driven imaging partnership to assess whether MRI-based biomarkers can guide personalized Alzheimer's therapy.
Summary
NeuroXT and Beth Israel Deaconess Medical Center are deepening their collaboration to develop AI tools that use standard MRI scans to predict how individual Alzheimer's patients will respond to treatment. The initial phase validated that NeuroXT's technology could estimate biomarkers typically requiring expensive PET scans. The expanded work will analyze data from patients who have been on Alzheimer's therapies for over a year, aiming to test whether these AI-derived imaging signals can guide real clinical decisions. If successful, this approach could make precision Alzheimer's care more accessible by replacing costly PET imaging with widely available MRI technology — a meaningful step toward earlier, more personalized intervention.
Detailed Summary
Alzheimer's disease remains one of the most costly and difficult conditions to treat, partly because predicting which patients will respond to a given therapy is still largely guesswork. A new expanded partnership between AI neuroimaging company NeuroXT and Beth Israel Deaconess Medical Center aims to change that by using machine learning applied to standard MRI scans to predict individual treatment responses.
The original collaboration, launched in August 2024, focused on a specific technical challenge: validating whether NeuroXT's AI could estimate Alzheimer's-related PET biomarkers — such as amyloid and tau burden — directly from MRI images. PET scans are the current gold standard for measuring these markers, but they are expensive, involve radiation exposure, and are not universally available. If MRI-derived AI estimates can reliably substitute, the barrier to biomarker-guided care drops significantly.
Under the newly signed expanded agreement, researchers will analyze longitudinal data from BIDMC patients who have been receiving Alzheimer's therapies for more than one year. The goal is to determine whether NeuroXT's imaging biomarkers can assess clinical utility — essentially, whether tracking these AI-generated signals over time helps predict who benefits from treatment and who does not.
The collaboration is led by neurologists Dr. Daniel Press and Dr. Chun Lim, lending institutional credibility to the work. NeuroXT also presented findings at a BIDMC symposium in October 2025 focused on early Alzheimer's biomarkers, suggesting the research is already informing clinical dialogue.
Key caveats apply. This is early-stage translational research, and no peer-reviewed outcomes data has been published yet. The company's claims about clinical utility remain to be validated in rigorous trials. Still, for health-conscious individuals and clinicians tracking Alzheimer's prevention and treatment, AI-driven neuroimaging biomarkers represent a genuinely promising direction — one that could eventually inform earlier diagnosis and more targeted interventions.
Key Findings
- NeuroXT's AI estimates Alzheimer's PET biomarkers from standard MRI, potentially replacing costly PET scans.
- Expanded study will use longitudinal patient data from over one year of Alzheimer's therapy to test clinical utility.
- Technology aims to predict individual treatment response, enabling more personalized Alzheimer's care.
- Collaboration led by BIDMC neurologists Dr. Daniel Press and Dr. Chun Lim adds institutional scientific credibility.
- If validated, MRI-based AI biomarkers could make precision Alzheimer's diagnosis more accessible and affordable.
Methodology
This is a news report summarizing a corporate partnership announcement from Longevity.Technology, a specialized longevity media outlet. It is based on a press release rather than a peer-reviewed publication. No primary data or clinical outcomes have been published yet.
Study Limitations
No peer-reviewed data has been published from either phase of this collaboration, so clinical utility claims are unverified. The article is based on a corporate press release, which carries inherent promotional bias. Readers should await published trial results before drawing conclusions about real-world applicability.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.